Abstract:Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson's disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.Compound 1 homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">CSV</a>)Kinase panel for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">CSV</a>)Crystal data for compound (R)-32; 1H NMR and HPLC traces for compounds 1, 4, 7, 19, 20, 21, 22, 23, 25, 26, 30, and 31; and table of geometric mean and geometric standard deviation of biochemical potency (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Brain Penetrant LRRK2 Inhibitor.

Selective Inhibitors of G2019S-LRRK2 Kinase Activity

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease

Leucine-Rich Repeat Kinases

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice is Eliminated by Familial Parkinson's Disease Mutation G2019S

Identification of peptides interfering with the LRRK2/PP1 interaction

Concurrent Optimizations of Efficacy and Blood-Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson's Disease Therapeutics

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model

18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson’s disease

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2)